Gavi, the Vaccine Alliance plans to help save 1 BILLION lives in the next 10 years with vaccines. That's double speed from the last 20 years. Like and share this post to show them support.
The ONE Campaign’s Post
More Relevant Posts
-
Our new white paper outlines key policy barriers that will need to be addressed to ensure patient access to novel adult combination vaccines for #flu and #COVID19. As these vaccines approach approval, alignment on strain selection, coverage and more is crucial. Read the full report, here: https://lnkd.in/emaHskZy
To view or add a comment, sign in
-
A new white paper from @Avalere outlines key policy barriers that will need to be addressed to ensure patient access to novel adult combination vaccines for #flu and #COVID19. As these vaccines approach approval, alignment on strain selection, coverage and more is crucial. The full report, here: buff.ly/44SYzcA
Adult Seasonal Combination Respiratory Vaccines: Policy Considerations | Avalere
https://avalere.com
To view or add a comment, sign in
-
One of the Top Reads of 2023: Developing the Next Generation of SARS-CoV-2 Vaccines The first generation of SARS-CoV-2 vaccines rolled out in record time in 2020, providing initial first-line protection against COVID-19. However, as COVID-19 continues to be a worldwide health problem, researchers are urgently investigating new vaccines to provide more potent and durable protection, including protection in various populations of patients for whom the first-generation vaccines are insufficient. While the first-generation vaccines provided an initial line of protection, there is a lot more to do. https://ow.ly/RB9o50QlWhP
Developing the Next Generation of SARS-CoV-2 Vaccines
To view or add a comment, sign in
-
Combination vaccines have been available for children for decades and their value has been well established in increasing convenience for both patients and HCPs, ultimately increasing vaccine coverage rates. These are the first Phase 3 results of an investigational Flu/COVID-19 vaccine for adults 50+ to demonstrate significantly higher immune responses of the combination vaccine versus the active comparators. Not just a convenience benefit!. https://lnkd.in/dZDU3rA7
To view or add a comment, sign in
-
ICYMI-Congratulations to Sapna Prasad and the Clarify Insights Services (CIS) team whose analysis conducted with Pfizer’s pneumococcal vaccines team has been published in the journal Vaccine. The CIS team worked with Pfizer to assess the impact of the 2019 shared clinical decision-making recommendations for the PCV13 vaccine in the US. The analysis showed the revised guidelines played a role in reducing vaccination uptake across vulnerable subgroups and immunocompromised patients. https://ow.ly/yfmB50PHePL #pneumococcal #vaccine
To view or add a comment, sign in
-
-
FDA Advisers Recommend Updating COVID-19 Vaccines for Fall The FDA advisory committee unanimously supports updating COVID-19 vaccines to target the JN.1 virus family ahead of the fall season. Key Points: Focus: JN.1 lineage for broader protection. Alignment: Matches WHO’s advice. Dominant Variant: KP.2 prevalent in the U.S. since April. Broad Protection: Believed to offer wider cross-protection. Vaccine Updates: Pfizer, Moderna, and Novavax can deliver updated shots for fall. Emphasis on having a third option for those hesitant about mRNA shots. #VaccineUpdate #COVID19 #FDA #PublicHealth #HealthNews #PandemicPreparedness #VirusProtection #Immunization #Biotechnology #VaccinationCampaign #Healthcare #VaccineResearch #PublicSafety #MedicalInnovation Link to article-https://lnkd.in/eD4eYFNM
To view or add a comment, sign in
-
Appointments for the updated #COVID19 vaccine are now available at Bartell Drugs! What should you know about the new COVID-19 vaccine? Here are some quick facts: ✔ The vaccine provides enhanced protection against currently circulating variants of COVID-19 ✔ Eligible individuals are those six months and older who have not received a COVID-19 vaccine in the past two months* ✔ It can be administered with other vaccines at the same appointment – think coverage against RSV, flu and COVID-19 in one fell swoop! *Bartell Drugs pharmacists are trained to immunize individuals three years and older. Read the full release to learn more: https://brtl.co/3LrZKHD
To view or add a comment, sign in
-
-
Only a limited number of combination vaccines are currently available for adults. This will likely change as multiple combination vaccines for respiratory illnesses are currently in development and set to launch over the next decade. But will current systems and pathways be able to accommodate these vaccines? A new report from Avalere finds there are several gaps: bit.ly/4dqme8n
To view or add a comment, sign in
-
CanSino Biologics Inc.康希诺生物 (SEHK:6185, SHSE:688185) announced the initiation of its #Tdcp Adolescent and Adult #vaccine Phase I trial. The trial has successfully enrolled its first participant, aiming to assess the safety and #immunogenicity of Tdcp in a randomized, double-blind, controlled way. This vaccine has been included in the routine immunization schedules of major developed countries. However, there is currently no approved vaccine of this kind in China. The successful market launch of Tdcp would address this gap in the domestic healthcare market. #QMPortfolio #QMHealthcare
To view or add a comment, sign in
-